# Advances in Molecular Imaging for the Early Detection and Management of Alzheimer’s Disease

## TL;DR

This paper discusses how molecular imaging, especially PET scans, helps detect Alzheimer's disease early, enabling better clinical management.

## Contribution

The paper presents a case study demonstrating the clinical utility of advanced PET imaging in early Alzheimer's diagnosis.

## Key findings

- PET imaging with amyloid and tau tracers enables early detection of Alzheimer's pathology.
- Molecular imaging can identify AD before significant cognitive decline occurs.

## Abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by impairments in memory and cognitive abilities. The development of new immunotherapies targeting beta-amyloid (Aβ) and tau protein deposition in the brain is ushering in great advances in clinical management. Advances in molecular imaging techniques, particularly positron emission tomography (PET) with amyloid and tau tracers, have facilitated the early detection of Alzheimer's pathology. We report a case of a 67-year-old patient presenting with mild cognitive impairment (MCI) who was confirmed to have AD on newer PET imaging. This report highlights the important role of molecular imaging in the early diagnosis of AD before significant clinical and functional decline sets in, thereby emphasizing its role in clinical practice.